dc.contributor.author | Cranage, Martin P. | |
dc.contributor.author | Fraser, Carol A. | |
dc.contributor.author | Cope, Alethea | |
dc.contributor.author | McKay, Paul F. | |
dc.contributor.author | Cole, Tom | |
dc.contributor.author | Mahmoud, A. Nasir | |
dc.contributor.author | Hall, Joanna | |
dc.contributor.author | Giles, Elaine | |
dc.contributor.author | Voss, Gerald | |
dc.contributor.author | Page, Mark | |
dc.contributor.author | Almond, Neil | |
dc.contributor.author | Shattock, Robin J. | |
dc.contributor.author | Seaman, Michael S. | |
dc.date.accessioned | 2012-01-03T04:46:11Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | Cranage, Martin P., Carol A. Fraser, Alethea Cope, Paul F. McKay, Michael S. Seaman, Tom Cole, A. Nasir Mahmoud, et al. 2011. Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 29(7): 1421-1430. | en_US |
dc.identifier.issn | 0264-410X | en_US |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:5978759 | |
dc.description.abstract | Optimum strategies to elicit and maintain antibodies at mucosal portals of virus entry are critical for the development of vaccines against human immunodeficiency virus (HIV). Here we show in non-human primates that a novel regimen of repeated intravaginal delivery of a non-adjuvanted, soluble recombinant trimeric HIV-1\(_{CN54}\) clade C envelope glycoprotein (gp140) administered in Carbopol gel can prime for B-cell responses even in the absence of seroconversion. Following 3 cycles of repeated intravaginal administration, throughout each intermenses interval, 3 of 4 macaques produced or boosted systemic and mucosally-detected antibodies upon intramuscular immunisation with gp140 formulated in AS01 adjuvant. Reciprocally, a single intramuscular immunisation primed 3 of 4 macaques for antibody boosting after a single cycle of intravaginal immunisation. Virus neutralising activity was detected against clade C and clade B HIV-1 envelopes but was restricted to highly neutralisation sensitive pseudoviruses. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier Science | en_US |
dc.relation.isversionof | doi:10.1016/j.vaccine.2010.12.034 | en_US |
dc.relation.hasversion | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060343/pdf/ | en_US |
dash.license | LAA | |
dc.subject | immunisation | en_US |
dc.subject | vagina | en_US |
dc.subject | HIV-gp140 | en_US |
dc.title | Antibody Responses after Intravaginal Immunisation with Trimeric HIV-1CN54 clade C gp140 in Carbopol Gel are Augmented by Systemic Priming or Boosting with an Adjuvanted Formulation | en_US |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en_US |
dc.relation.journal | Vaccine | en_US |
dash.depositing.author | Seaman, Michael S. | |
dc.date.available | 2012-01-03T04:46:11Z | |
dash.affiliation.other | HMS^Medicine- Beth Israel-Deaconess | en_US |
dc.identifier.doi | 10.1016/j.vaccine.2010.12.034 | * |
dash.authorsordered | false | |
dash.contributor.affiliated | Seaman, Michael | |